Biscayne Neurotherapeutics
Is a clinical-stage biotechnology company developing novel therapies for difficult-to-treat neurological disorders. Biscayne’s lead compound, BIS-001, is in clinical development for the treatment of refractory forms of epilepsy.


Biscayne Neurotherapeutics is a clinical-stage biotechnology company developing novel drugs for central nervous system (CNS) disorders, focusing initially on refractory epilepsy. Biscayne’s lead compound, BIS-001,has shown dramatic efficacy in preclinical models of difficult-to-treat epileptic conditions. BIS-001 successfully completed a Phase 1a safety study and Biscayne expects to initiate a Phase 1b trial later this year. Biscayne’s technology is licensed from Harvard University, Yale University and the University of South Florida. Learn More


Biscayne’s platform is based on a unique synthetic form of huperzine A, an extract of a traditional Chinese medicine with a long history of safe use in neurological conditions. Huperzine A is a highly potent acetylcholinesterase inhibitor with demonstrated efficacy in models of severe epilepsy. Learn More


Biscayne Announces Formation of Biscayne Neurotherapeutics and Completion of Series B Financing

Biscayne Pharmaceuticals Presents Data On Novel Antiepileptic Agent Bis-001 At Eilat Conference On New Antiepileptic Drugs

Biscayne Pharmaceuticals Presents Data At 2015 Aes Meeting Confirming Bis-001 Is A Novel Mechanism, Highly Potent And Well-Tolerated Anti-Epileptic Drug